MHRA approves Seagen’s Tukysa for HER2-positive breast cancer by Lucy Parsons | Feb 23, 2021 | News | 0 Drug approved in a combination regimen for advanced breast cancer patients Read More
New Herceptin combo could keep breast cancers at bay by Anna Smith | Jun 28, 2019 | News | 0 Guiding chemotherapy to a tumour by attaching it to the antibody-based target drug Herceptin is effective at treating women with breast cancer who have no other treatment options. Read More
AZ announces Phase I DS-8201 results by Anna Smith | May 2, 2019 | News | 0 Approximately one in five breast and gastric cancers are HER2-positive. Read More